🔗 Share this article

As the US undertakes historic revisions to its vaccination schedules, an unexpected name has surfaced somewhat surprisingly: Tracy Beth Høeg, a US-based physician and epidemiologist who rose to prominence by expressing skepticism about coronavirus vaccines throughout the global health crisis and has focused upon alleged deaths after COVID-19 vaccination in her recent time at the FDA.

Proposed Overhauls to Childhood Vaccine Program

Public health authorities were set to announce sweeping changes to the childhood vaccine schedule in December, synchronizing the US with the Danish vaccine program, it is understood – a major change that would put the US out of alignment with a large portion of the international standard with no evidence for public health gain. The planned update has been delayed until the coming year.

Rather than the top vaccines chief, Høeg is listed to speak at the gathering. She was newly appointed interim head of the FDA’s drug evaluation center, the fifth appointee to lead the division this year.

A Shift at the Agency

Høeg's temporary position might represent a tighter collaboration between the pharmaceutical and vaccine centers as Dr. Høeg and Dr. Prasad consolidate power at the FDA – and it points to a renewed priority upon rolling back already-approved vaccines at the FDA.

The new acting director has repeatedly called for ending certain childhood immunization guidelines in the US in order to be more similar to Denmark's approach, a nation with comprehensive healthcare and a number of inhabitants roughly the population of the state of Wisconsin.

In her initial comments, she has persisted in emphasizing on vaccination policy – typically the responsibility of Prasad, head of the FDA’s CBER – rather than drug regulation.

Doubts Over Qualifications

Høeg has no apparent track record in drug development, approval processes or leadership, which has been typical for previous heads of the biologics center. She has served at the FDA as a key advisor to the FDA chief and CBER since earlier this year.

“It seems she lacks to have the requisite experience” for overseeing the pharmaceutical oversight division, remarked Jonathan Howard. “She’s never run a randomized controlled trial. She lacks experience in managing a major agency. She has no expertise in pharmaceutical oversight.”

Previous commissioners of the center would “understand legal statutes and the research of drug development”, noted Dr. Janet Woodcock. “Clearly, she has not acquired the kind of background that former directors who led CBER have had.”

CDER has an vast range of responsibilities at the FDA, Woodcock emphasized.

“Everybody just zeroes in on the innovative therapies, but the generic program authorizes thousands of generic medications. There is also a biosimilars program, over-the-counter program and more, and each of these need to be looked after,” Woodcock explained. “The area you overlook, that is precisely what that I always told people is going to come back to haunt you.”

There is also, a significant administrative element to the position, which oversees over 5,000 personnel. “It’s a huge management job, if you perform it correctly,” the former official said.

Agency Reaction and Contentious Initiatives

In response to concerns about Høeg’s credentials and whether this selection signifies greater collaboration among agency officials on immunizations, a press secretary responded that the “inquiries stem from incorrect assumptions”.

“This background is consistent with the duties of her position,” the representative stated, pointing to the period Høeg spent counseling the FDA commissioner on “pharmaceutical safety and approval science, including computational safety modeling and vaccine surveillance”.

As acting director, Høeg assumes responsibility for the commissioner’s controversial fast-track approval initiative, a contentious rapid therapy clearance system that allegedly troubled her predecessors. “How are these therapies being chosen for this expedited pathway? Who is making the decisions?” Dr. Howard asked. “There is a lot of lack of transparency occurring at the agency right now.”

Overall, he remarked, “the Food and Drug Administration seems to be moving towards more relaxed oversight of all drugs, except for vaccines.”

Public Track Record on Immunizations

With vaccines, Dr. Høeg has a clearer, if concerning, track record, Howard observe. She published a research paper using unverified crowd-sourced reports to estimate the rate of myocarditis following COVID-19 immunization. She counseled the state of Florida chief medical officer Joseph Ladapo, who was said to have modified findings to imply Covid vaccines are riskier than they are.

Part of her “wish list” for the current administration included revising guidelines for novel immunizations and discontinuing “optional” vaccines, she remarked post-election on a podcast. At the FDA, Høeg has according to sources suggested preventing adolescent males from getting COVID-19 vaccinations.

“She’s an all-around dogmatist who starts off with her conclusions and tailors the evidence to accommodate the science in a highly misleading, untruthful way,” Dr. Howard said.

Consolidating Power and a “Revenge Tour”

Dr. Høeg aligned with other dissenters, {like|